Introduction
============

Age-related macular degeneration (AMD) is still the primary cause of visual impairment and blindness in patients older than 60 years in developed countries.[@b1-opth-12-587] In the neovascular form of AMD, the choroidal neovascularization (CNV) beneath the macula leads to fibrous metaplasia, permanent loss of photoreceptors, and disciform scarring, which often results in the loss of central vision.[@b2-opth-12-587]

Large-scale clinical trials have shown that monthly or bimonthly intravitreal injection of vascular endothelial growth factor (VEGF) antagonists prevents vision loss and may even improve visual acuity in patients with neovascular AMD.[@b3-opth-12-587],[@b4-opth-12-587] However, it is important to note that VEGF is not the only causative factor in CNV. In particular, free radicals and oxidized lipoproteins in the aging retina are major local triggers of parainflammation, which is the chronic status responsible for the initiation and progression of age-related chorioretinal damage.[@b5-opth-12-587],[@b6-opth-12-587] Thus, inflammation itself plays an important role in the pathogenesis of CNV and administration of a topical nonsteroidal anti-inflammatory drug (NSAID) has been shown to supplement the effectiveness of anti-VEGF agents in reducing central retinal thickness (CRT)[@b7-opth-12-587],[@b8-opth-12-587] and the rate of re-injection in CNV.[@b9-opth-12-587] A recent assessment of the vitreous penetration of NSAIDs and their effects on prostaglandin E~2~ (PGE~2~) revealed a significant reduction in vitreous PGE~2~ levels in response to indomethacin, bromfenac, and nepafenac.[@b10-opth-12-587] Considering these results, in this study, we prospectively evaluated whether the addition of 0.5% indomethacin eye drops three times a day (TID) to the standard treatment of intravitreal ranibizumab (IVR) injections would provide better efficacy than that achieved with ranibizumab alone in patients with CNV.

Participants and methods
========================

Study design
------------

This was an open-label, pilot study in eyes affected by new neovascular AMD. This study was conducted in the Ophthalmic Center of "Spedali Civili di Brescia", according to the ethical principles of the Declaration of Helsinki. The institutional review board of the "Spedali Civili di Brescia" hospital approved the study protocol (registered with [ClinicalTrials.gov](http://ClinicalTrials.gov), identifier NCT03261635). All study participants provided written informed consent.

Participants
------------

Sixty consecutive participants were enrolled from September 2016 to March 2017 at the Spedali Civili Ophthalmic Center (Spedali Civili di Brescia) in Brescia, Italy. Patients were randomized (online statistical computing web programming [www.graphpad.com/quickcalcs](http://www.graphpad.com/quickcalcs)) at a 1:1 ratio into the following two groups: monotherapy with IVR injections (ranibizumab monotherapy \[RM\] group; n=29) and IVR injections plus off-label topical 0.5% indomethacin eye drops (ranibizumab plus indomethacin \[RI\] group; n=29). One patient per group was excluded because they moved to another eye clinic after the initial ranibizumab-loading phase.

Inclusion and exclusion criteria
--------------------------------

Inclusion criteria were as follows: 1) provision of written informed consent, 2) age \>40 years, and 3) presence of treatment-naive neovascular AMD, which was defined as neovascularization, fluid, or hemorrhage underneath the fovea. The presence of new active CNV was confirmed by the evidence of leakage on fluorescein angiography and fluid on spectral domain optical coherence tomography (OCT) (Spectralis OCT; Heidelberg Engineering, Heidelberg, Germany). The diagnosis was made by one investigator (AR) and thereafter confirmed by the second investigator (EG).

Exclusion criteria were as follows: 1) any prior intravitreal or retinal laser treatment, 2) pathological myopia (\>7 D), 3) any concomitant eye disease, and 4) corneal epithelial defects or any condition that would affect the cornea.

Study treatments
----------------

Participants in both groups received an initial loading phase of 3 monthly IVR. Retreatment criteria for further injections performed by a masked examiner were as follows: 1) any intraretinal or subretinal fluid on OCT, 2) new or persistent hemorrhage, and 3) decrease in visual acuity. In the case of the absence of fluid on OCT or visual acuity drop, a fluorescein leakage of \>25% of the lesion circumference or the expansion of CNV was needed for retreatment in suspicious cases.

Patients in the RI group were given a bottle of eye drops of 0.5% indomethacin ophthalmic solution for self-administration, which was provided free of charge by Alfa Intes Srl (Casoria, Italy). Over the 12-month study period, indomethacin was administered at a dose of one drop in the study eye TID. To verify and increase their compliance, patients were asked to bring their used bottles of indomethacin during each visit.

Clinical evaluation
-------------------

The following examinations were performed at each visit by a blinded examiner: 1) measurement of best-corrected visual acuity (BCVA) as measured by the Early Treatment Diabetic Retinopathy study letter score, 2) fully dilated slit-lamp ophthalmic examination, 3) OCT (Spectral Domain Spectralis OCT) measurement of CRT, and 4) evaluation of adverse ocular events. Fundus photography (fluorescein and indocyanine green angiography) was performed at baseline, 3 months, and 12 months and at any monthly visit between 4 and 11 months on the basis of retreatment criteria.

Endpoints and outcome measures
------------------------------

Outcome measures were as follows: 1) mean change in study eye visual acuity; 2) mean change in CRT; 3) mean number of IVR injections over the 6-month period; and 4) adverse ocular events at 12 months.

Statistical analyses
--------------------

To determine if there was a significant difference in changes in BCVA and CRT, repeated measures of analysis of variance with Greenhouse--Geisser and Bonferroni corrections were performed. Independent samples *t*-tests were conducted to determine the statistical significance of differences in visual acuity, CRT, and number of injections between the RM and RI groups. All statistical analyses were performed using the SPSS software V.20 (IBM Corporation, Armonk, NY, USA). *P*-values \<0.05 were considered significant, and all values are reported as mean ± standard deviation.

Results
=======

Baseline demographic and clinical data of the participants are shown in [Table 1](#t1-opth-12-587){ref-type="table"}. In general, the baseline demographics between the two groups were well matched, with no significant differences between the groups. All 58 patients completed the study.

Visual acuity
-------------

The mean BCVA score improved significantly in both treatment groups, with the largest mean change observed in the RI group from baseline ([Figure 1](#f1-opth-12-587){ref-type="fig"}).

The mean change in BCVA from baseline to 12 months was −0.12±0.04 LogMAR in the RM group (*P*=0.04) and −0.20±0.04 LogMAR in the RI group (*P*=0.001), with the degree of change being significantly different between the two groups (*P*=0.04).

At 12 months, the mean BCVA in the RI group (0.35±0.14 LogMAR) was significantly higher than that in the RM group (0.45±0.18 LogMAR; *P*=0.04). [Table 2](#t2-opth-12-587){ref-type="table"} shows the changes in visual acuity at key time points.

CRT
---

A constant and significant reduction in mean CRT was observed in the RM group (−101±12.6 µm; *P*\<0.0001) and in the RI group (−134±14.8 µm; *P*\<0.0001) from baseline to 12 months. [Figure 2](#f2-opth-12-587){ref-type="fig"} shows the changes in CRT in both groups over the 12-month treatment period. At 12 months, the mean CRT in the RM group (316±41.2 µm) was significantly higher than that in the RI group (287±31.5 µm; *P*=0.004). Changes in CRT over the 12-month treatment period are shown in [Table 2](#t2-opth-12-587){ref-type="table"}.

Number of injections
--------------------

The mean number of required IVR injections was 7.38±0.78 in the RM group and 6.34±0.67 in the RI group (*P*\<0.001).

Safety and adverse events
-------------------------

No serious adverse events were observed during the study period. There was no significant difference in the number of adverse ocular events described by either group. Mild burning/stinging was reported more frequently in the RI group, while pain was similar between groups. Adverse ocular events are reported in [Table 3](#t3-opth-12-587){ref-type="table"}. No issues regarding compliance with the indomethacin therapy were recorded for any patient.

Discussion
==========

The results of this prospective pilot study suggest that the topical administration of indomethacin, when used in combination with ranibizumab, may produce further improvements in BCVA, retinal thickness, and the number of required IVR injections.

Although anti-VEGF agents constitute the first line of therapy against CNV in AMD, topical NSAIDs targeting specific inflammatory processes have recently been tested both experimentally[@b11-opth-12-587],[@b12-opth-12-587] and clinically and have been found to ameliorate AMD more effectively and synergistically.[@b7-opth-12-587]--[@b9-opth-12-587],[@b13-opth-12-587] Moreover, these results are supported by the recent finding of significant vitreous penetration by NSAIDs, which reach therapeutic concentrations that allow a significant reduction in PGE~2~ and IL-8 vitreous production.[@b10-opth-12-587],[@b14-opth-12-587],[@b15-opth-12-587]

We believe that the combination of IVR and indomethacin has the potential to reduce the burden associated with monthly IVR injections. Indeed, the results of this pilot study suggest that the addition of topical 0.5% indomethacin may result in a significant reduction in the 12-month CRT in patients with neovascular AMD, with a small but significant BCVA improvement over IVR monotherapy.

The anatomical and functional improvements shown in this study are consistent with the results of previous similar studies with other topical NSAIDs, including ketorolac,[@b7-opth-12-587],[@b8-opth-12-587] bromfenac,[@b9-opth-12-587],[@b13-opth-12-587] and nepafenac.[@b16-opth-12-587] Although a comparison between different studies is not feasible, the results coming from this study show a greater synergistic effect with topical 0.5% indomethacin. This might be explained by lower PGE~2~ vitreous levels after treatment with 0.5% indomethacin, compared to 0.09% bromfenac and 0.1% nepafenac in a prospective, investigator-masked, and randomized study.[@b10-opth-12-587]

Interestingly, we observed that the addition of indomethacin resulted in a significant reduction in the number of IVR injections, which could be a pivotal class effect with NSAIDs. Moreover, this finding is consistent with a previous report by Gomi et al,[@b9-opth-12-587] wherein patients who were prescribed bromfenac in combination with IVR required one less IVR injection during the first 6 months of therapy. Reduced frequency of IVR injections, although slight, is greatly beneficial in light of chronic and expensive (the mean national Medicare drug payment per anti-VEGF injection in the USA is reported to be \$1,078 per injection)[@b17-opth-12-587] intravitreal therapy, which can be associated with serious adverse events such as endophthalmitis, retinal tears, and retinal detachment.

No serious adverse events were reported in our study. The results show that the treatments were well tolerated in all groups, with a safety profile comparable to that observed in previous studies. Furthermore, compliance with eye drop use was very high and the incidence of reported adverse events was mild to moderate.

Our study has a few limitations: first, we included a limited number of patients in a pilot study design. Second, the evaluation of adverse events was limited to eye and headache symptoms. Third, we only assessed indomethacin TID. Further studies with a larger sample size, various dosing regimens, and more in-depth follow-up are warranted to validate the results of this pilot study, especially considering the substantial visual decline during the late stages of neovascular AMD.[@b18-opth-12-587]

Conclusion
==========

The results of this pilot study suggest that topical 0.5% indomethacin administered TID with IVR has an additive effect on CRT reduction in CNV. As previously reported, further larger studies are needed to confirm these data, especially evaluating the long-term efficacy of NSAIDs because AMD is a chronic disease with an inflammatory component. In particular, careful attention should be paid to the corneal complications associated with long-term use of topical NSAIDs.

This study was presented in the AAO 2016 Meeting; Chicago, IL, USA. October 15, 2016 -- October 18, 2016.
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###### 

Baseline patient characteristics

  --------------------------------------------------------
                                   RM group\   RI group\
                                   (n=29)      (n=29)
  -------------------------------- ----------- -----------
  Sex, n (%)                                   

   Male                            13 (44.8)   12 (41.4)

   Female                          16 (55.2)   17 (58.6)

  Age (years)                                  

   Mean ± SD                       75.1±8.9    75.0±7.1

   Range                           59--87      58--83

  Visual acuity                                

   Mean ± SD (LogMAR)              0.56±0.25   0.56±0.29

   Range                           0.1--1      0.1--1

  CRT (µm)                                     

   Mean ± SD                       417±81.9    422±73.6

  Lesion composition, n (%)                    

   Classic/predominantly classic   13 (44.8)   12 (41.4)

   Minimally classic/occult        16 (55.2)   17 (58.6)
  --------------------------------------------------------

**Notes:** RM group: monotherapy with monthly 0.5 mg intravitreal ranibizumab injections; RI group: monthly 0.5 mg intravitreal ranibizumab injections with topical indomethacin 0.5% eye drops three times a day.

**Abbreviations:** CRT, central retinal thickness; RI, ranibizumab plus indomethacin; RM, ranibizumab monotherapy.

###### 

Changes in visual acuity and central retinal thickness over 12 months of treatment

                              Baseline    2 months                                                4 months                                                6 months                                                8 months                                                10 months                                               12 months
  --------------------------- ----------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------
  Visual acuity (mean ± SD)                                                                                                                                                                                                                                                                                                       
   RM group                   0.56±0.25   0.47±0.22[\*](#tfn4-opth-12-587){ref-type="table-fn"}   0.45±0.24[\*](#tfn4-opth-12-587){ref-type="table-fn"}   0.42±0.20[\*](#tfn4-opth-12-587){ref-type="table-fn"}   0.42±0.20[\*](#tfn4-opth-12-587){ref-type="table-fn"}   0.42±0.20[\*](#tfn4-opth-12-587){ref-type="table-fn"}   0.45±0.18[\*](#tfn4-opth-12-587){ref-type="table-fn"}
   RI group                   0.56±0.29   0.43±0.19[\*](#tfn4-opth-12-587){ref-type="table-fn"}   0.40±0.20[\*](#tfn4-opth-12-587){ref-type="table-fn"}   0.38±0.17[\*](#tfn4-opth-12-587){ref-type="table-fn"}   0.36±0.14[\*](#tfn4-opth-12-587){ref-type="table-fn"}   0.35±0.13[\*](#tfn4-opth-12-587){ref-type="table-fn"}   0.35±0.14[\*](#tfn4-opth-12-587){ref-type="table-fn"}
   *P*-value                  0.83        0.43                                                    0.39                                                    0.41                                                    0.18                                                    0.14                                                    0.04
  CRT (mean ± SD)                                                                                                                                                                                                                                                                                                                 
   RM group                   417±82      338±50[\*](#tfn4-opth-12-587){ref-type="table-fn"}      335±49[\*](#tfn4-opth-12-587){ref-type="table-fn"}      327±52[\*](#tfn4-opth-12-587){ref-type="table-fn"}      322±39[\*](#tfn4-opth-12-587){ref-type="table-fn"}      326±38[\*](#tfn4-opth-12-587){ref-type="table-fn"}      316±41[\*](#tfn4-opth-12-587){ref-type="table-fn"}
   RI group                   422±74      327±37[\*](#tfn4-opth-12-587){ref-type="table-fn"}      309±43[\*](#tfn4-opth-12-587){ref-type="table-fn"}      300±43[\*](#tfn4-opth-12-587){ref-type="table-fn"}      293±36[\*](#tfn4-opth-12-587){ref-type="table-fn"}      290±33[\*](#tfn4-opth-12-587){ref-type="table-fn"}      287±32[\*](#tfn4-opth-12-587){ref-type="table-fn"}
   *P*-value                  0.93        0.35                                                    0.03                                                    0.03                                                    0.005                                                   \<0.001                                                 0.004

**Notes:** *P*-values presented are for the difference between the two groups. RM group: monotherapy with monthly 0.5 mg intravitreal ranibizumab injections; RI group: monthly 0.5 mg intravitreal ranibizumab injections with topical indomethacin 0.5% eye drops three times a day.

*P*\<0.05 compared with baseline value for the same group.

**Abbreviations:** CRT, central retinal thickness; RI, ranibizumab plus indomethacin; RM, ranibizumab monotherapy.

###### 

Ocular adverse events in the study eyes during the 12-month study period

                           RM group, n (%)   RI group, n (%)
  ------------------------ ----------------- -----------------
  Abnormal sensation       9 (31)            12 (41)
  Burning/stinging         14 (48)           16 (55)
  Eye pain                 4 (14)            4 (14)
  Itchy eye                6 (21)            8 (28)
  Headache                 4 (14)            3 (10)
  Sore eyelid              4 (14)            4 (14)
  Retinal hemorrhage       1 (3)             0 (0)
  Foreign body sensation   10 (34)           16 (55)
  Conjunctivitis           6 (21)            4 (14)
  Dry eye                  7 (24)            9 (31)
  Eye strain               8 (28)            9 (31)
  Light sensitivity        12 (41)           11 (38)
  Floaters                 15 (30)           14 (48)

**Notes:** RM group: monotherapy with monthly 0.5 mg intravitreal ranibizumab injections; RI group: monthly 0.5 mg intravitreal ranibizumab injections with topical indomethacin 0.5% eye drops three times a day.

**Abbreviations:** RI, ranibizumab plus indomethacin; RM, ranibizumab monotherapy.
